Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.49 |
| ▸ | GPR119 | Q8TDV5 | 17/20 | 0.47 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | JAK1 | P23458 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL389150 | 0.88 | GPR119 (0.50) | FAAHGPR119JAK2JAK1 | |
| SCHEMBL392079 | 0.85 | GPR119 (0.48) | FAAHGPR119JAK2JAK1 | |
| SCHEMBL389281 | 0.85 | GPR119 (0.47) | FAAHGPR119JAK2JAK1 | |
| SCHEMBL390987 | 0.80 | GPR119 (0.52) | FAAHGPR119 | |
| SCHEMBL4905311 | 0.79 | GPR119 (0.47) | FAAHGPR119JAK2JAK1 | |
| SCHEMBL391561 | 0.79 | GPR119 (0.52) | FAAHGPR119 | |
| SCHEMBL13989317 | 0.78 | FAAH (0.61) | FAAHGPR119 | |
| SCHEMBL4903274 | 0.77 | GPR119 (0.46) | FAAHGPR119JAK2JAK1 | |
| SCHEMBL391021 | 0.75 | GPR119 (0.49) | FAAHGPR119JAK2JAK1 | |
| SCHEMBL390516 | 0.75 | GPR119 (0.51) | FAAHGPR119JAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080312281-A1 | G-Protein Coupled Receptor (Gpr116) Agonists and Use Thereof for Treating Obesity and Diabetes | PROSIDION LIMITED (GB) | 2008-12-18 | — | — | US | disclosed |
| US-20080312281-A1 | G-Protein Coupled Receptor (Gpr116) Agonists and Use Thereof for Treating Obesity and Diabetes | PROSIDION LIMITED (GB) | 2008-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312281-A1 | G-Protein Coupled Receptor (Gpr116) Agonists and Use Thereof for Treating Obesity and Diabetes | GPR119, GCGR, GPR65 | FAAH 579/4885GPR119 1/4885JAK2 3297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.